BioSante Pharmaceuticals to Present at Friedland Capital's Biotech, Medical and Healthcare Conference.

Business Editors/Health/Medical Writers

BIOWIRE2K

LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--Sept. 19, 2003

BioSante Pharmaceuticals, Inc. (OTCBB:BISP) announced today that its president and chief executive officer Stephen M. Simes will present at Friedland Capital's Biotech, Medical and Healthcare Conference featuring companies covered by the research firm, J. M. Dutton & Associates in New York City on September 24 at 9:40 a.m. ET. The audio webcast will be available "live," then archived for 60 days at: www.friedlandcapitalevents.com/duttonwebcast.htm

This Friedland Capital Conference will bring together publicly-traded companies in the pharmaceutical and biotech industries. During his presentation Mr. Simes will present BioSante's corporate message to key members of the investment community including portfolio managers, analysts, brokers and investment bankers. Investors interested in attending the luncheon should contact Friedland Capital at 303-355-6566 or RSVP online to attend (www.friedlandcapitalevents.com).

Mr. Simes also is scheduled to present at the UBS Global Life Sciences Conference in New York City on Tuesday, September 23, 2003, at 3:00 p.m. ET. The audio portion of that presentation can be accessed via the UBS website www.ibb.ubs.com. Follow the link for the webcast under the Global Life Sciences Conference heading. A replay will begin approximately three hours after the presentation and will be available until October 25.

About BioSante Pharmaceuticals, Inc.

BioSante is an emerging pharmaceutical company developing a pipeline of hormone therapy products to treat both men and women. BioSante also is developing its nanoparticulate-based platform technology (CAP) for novel vaccines, vaccine adjuvants and drug delivery systems including oral administration of proteins, such as insulin. Additional information is available online at www.biosantepharma.com.

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The statements regarding BioSante contained in this press release that are not historical in nature, particularly those that utilize terminology such as "may," "will," "should," "likely," "expects," "anticipates," "estimates," "believes" or "plans," or comparable terminology, are forward-looking statements. Important factors known to BioSante that cause actual results to differ materially from those expressed in such forward-looking statements are the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance, and other factors identified and discussed from time to time in BioSante's filings with the Securities and Exchange Commission, including those factors discussed on pages 17 to 23 of BioSante's Form 10-KSB, which discussion also is incorporated herein by reference.